An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

NCT02116803 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: dovitinib
DRUG: fulvestrant

Sponsor

Novartis Pharmaceuticals